SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '6fdy'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1IEP_A_STIA201_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	6fdy	- (-)	7 / 12	LEU U 20 VAL U 28 ALA U 42 PHE U 93 GLY U 97 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.83A	1iepA-6fdyU: 22.0	1iepA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1IEP_A_STIA201_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	6fdy	- (-)	7 / 12	LEU U 20 VAL U 28 ALA U 42 PHE U 93 GLY U 97 LEU U 144 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.73A	1iepA-6fdyU: 22.0	1iepA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1IEP_B_STIB202_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	6fdy	- (-)	7 / 12	LEU U 20 VAL U 28 ALA U 42 PHE U 93 GLY U 97 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.88A	1iepB-6fdyU: 21.8	1iepB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1OPJ_A_STIA3_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	LEU U 20 VAL U 28 ALA U 42 VAL U 75 PHE U 93 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.2A)	0.75A	1opjA-6fdyU: 21.7	1opjA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1OPJ_B_STIB4_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	7 / 12	VAL U 28 ALA U 42 VAL U 75 PHE U 93 GLY U 97 ALA U 156 ASP U 157	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.99A	1opjB-6fdyU: 21.6	1opjB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EUF_B_LQQB401_1 (CELL DIVISION PROTEIN KINASE 6)	6fdy	- (-)	6 / 12	VAL U 75 ASP U 98 ASN U 142 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 (-4.8A) None DB8 U 301 (-4.5A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.54A	2eufB-6fdyU: 26.7	2eufB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2GQG_A_1N1A501_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	8 / 12	LEU U 20 ALA U 42 LYS U 44 VAL U 75 PHE U 93 GLY U 97 LEU U 144 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.67A	2gqgA-6fdyU: 25.0	2gqgA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2GQG_B_1N1B502_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	7 / 12	VAL U 28 ALA U 42 LYS U 44 VAL U 75 GLY U 97 LEU U 144 ALA U 156	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.64A	2gqgB-6fdyU: 25.0	2gqgB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_A_STIA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	VAL U 28 ALA U 42 PHE U 93 GLY U 97 ALA U 156 ASP U 157	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.83A	2hyyA-6fdyU: 22.1	2hyyA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_A_STIA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	VAL U 28 ALA U 42 PHE U 93 GLY U 97 LEU U 144 ALA U 156	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.73A	2hyyA-6fdyU: 22.1	2hyyA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_B_STIB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	VAL U 28 ALA U 42 PHE U 93 GLY U 97 LEU U 144 ALA U 156	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.71A	2hyyB-6fdyU: 22.2	2hyyB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ITY_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	6fdy	- (-)	8 / 12	LEU U 20 GLY U 21 VAL U 28 ALA U 42 LYS U 44 LEU U 89 GLY U 97 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 ( 4.9A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) None DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	0.68A	2ityA-6fdyU: 22.6	2ityA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ITY_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	6fdy	- (-)	8 / 12	LEU U 20 GLY U 21 VAL U 28 ALA U 42 LYS U 44 LEU U 89 LEU U 144 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.9A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) None DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	0.83A	2ityA-6fdyU: 22.6	2ityA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2XP2_A_VGHA9000_1 (TYROSINE-PROTEIN KINASE RECEPTOR)	6fdy	- (-)	6 / 9	LEU U 20 VAL U 28 ALA U 42 GLY U 97 LEU U 144 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	0.64A	2xp2A-6fdyU: 5.4	2xp2A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	5 / 10	LEU U 20 VAL U 28 LYS U 44 VAL U 75 PHE U 93	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A)	0.69A	3cs9A-6fdyU: 21.8	3cs9A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	5 / 10	LEU U 20 VAL U 28 VAL U 75 PHE U 93 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 (-3.6A)	0.92A	3cs9A-6fdyU: 21.8	3cs9A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G0F_A_B49A9001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	6fdy	- (-)	7 / 11	LEU U 20 VAL U 28 ALA U 42 CYH U 94 GLY U 97 ASP U 98 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 (-4.2A) DB8 U 301 ( 4.1A) None DB8 U 301 (-4.8A)	0.75A	3g0fA-6fdyU: 21.6	3g0fA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G0F_B_B49B9001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	6fdy	- (-)	6 / 10	LEU U 20 VAL U 28 ALA U 42 CYH U 94 GLY U 97 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 (-4.2A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	0.73A	3g0fB-6fdyU: 21.9	3g0fB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3GVU_A_STIA1001_1 (TYROSINE-PROTEIN KINASE ABL2)	6fdy	- (-)	7 / 12	LEU U 20 VAL U 28 ALA U 42 VAL U 75 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.87A	3gvuA-6fdyU: 22.2	3gvuA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IK3_A_0LIA1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	5 / 12	ALA U 42 VAL U 75 HIS U 135 LEU U 144 ALA U 156	DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) None DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.64A	3ik3A-6fdyU: 21.8	3ik3A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IK3_B_0LIB2_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	5 / 12	ALA U 42 VAL U 75 HIS U 135 LEU U 144 ALA U 156	DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) None DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.67A	3ik3B-6fdyU: 21.6	3ik3B-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3K5V_A_STIA2_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	VAL U 28 ALA U 42 PHE U 93 GLY U 97 LEU U 144 ALA U 156	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.75A	3k5vA-6fdyU: 21.6	3k5vA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3K5V_B_STIB2_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	VAL U 28 ALA U 42 PHE U 93 GLY U 97 LEU U 144 ALA U 156	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.72A	3k5vB-6fdyU: 21.3	3k5vB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MS9_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	LEU U 20 VAL U 28 ALA U 42 PHE U 93 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.68A	3ms9A-6fdyU: 21.7	3ms9A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MS9_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	LEU U 20 VAL U 28 ALA U 42 PHE U 93 LEU U 144 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.70A	3ms9A-6fdyU: 21.7	3ms9A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	LEU U 20 VAL U 28 ALA U 42 PHE U 93 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.69A	3mssA-6fdyU: 21.8	3mssA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	LEU U 20 VAL U 28 ALA U 42 PHE U 93 LEU U 144 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.72A	3mssA-6fdyU: 21.8	3mssA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	LEU U 20 VAL U 28 ALA U 42 PHE U 93 GLY U 97 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 ( 4.2A)	0.71A	3mssB-6fdyU: 21.8	3mssB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_C_STIC1_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	LEU U 20 VAL U 28 ALA U 42 PHE U 93 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.72A	3mssC-6fdyU: 21.8	3mssC-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_C_STIC1_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	LEU U 20 VAL U 28 ALA U 42 PHE U 93 LEU U 144 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.72A	3mssC-6fdyU: 21.8	3mssC-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_D_STID1_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	LEU U 20 ALA U 42 PHE U 93 GLY U 97 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.86A	3mssD-6fdyU: 21.8	3mssD-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_D_STID1_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 12	LEU U 20 ALA U 42 PHE U 93 GLY U 97 LEU U 144 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.76A	3mssD-6fdyU: 21.8	3mssD-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3PYY_B_STIB4_1 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	6fdy	- (-)	6 / 12	LEU U 20 VAL U 28 ALA U 42 VAL U 75 LEU U 144 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.77A	3pyyB-6fdyU: 21.7	3pyyB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	7 / 12	LEU U 20 ALA U 42 GLU U 62 VAL U 75 PHE U 93 GLY U 97 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 (-3.6A) None DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	1.05A	3ue4A-6fdyU: 24.4	3ue4A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	7 / 12	LEU U 20 ALA U 42 LYS U 44 VAL U 75 PHE U 93 GLY U 97 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	0.63A	3ue4A-6fdyU: 24.4	3ue4A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UE4_B_DB8B601_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	7 / 12	LEU U 20 VAL U 28 ALA U 42 VAL U 75 PHE U 93 GLY U 97 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	0.63A	3ue4B-6fdyU: 24.4	3ue4B-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UG2_A_IREA1_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	6fdy	- (-)	7 / 12	LEU U 20 VAL U 28 ALA U 42 LYS U 44 LEU U 89 GLY U 97 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) None DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	0.49A	3ug2A-6fdyU: 23.3	3ug2A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UG2_A_IREA1_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	6fdy	- (-)	7 / 12	LEU U 20 VAL U 28 ALA U 42 LYS U 44 LEU U 89 MET U 91 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) None DB8 U 301 (-4.8A) DB8 U 301 (-4.8A)	0.62A	3ug2A-6fdyU: 23.3	3ug2A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZD_A_LEVA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	6fdy	- (-)	5 / 12	LEU U 20 VAL U 28 ALA U 42 CYH U 94 GLY U 97	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 (-4.2A) DB8 U 301 ( 4.1A)	0.48A	3wzdA-6fdyU: 21.4	3wzdA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	6fdy	- (-)	7 / 12	LEU U 20 VAL U 28 ALA U 42 LYS U 44 PHE U 93 GLY U 97 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	0.75A	4ag8A-6fdyU: 20.9	4ag8A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	6fdy	- (-)	7 / 11	LEU U 20 ALA U 42 VAL U 75 PHE U 93 CYH U 94 GLY U 97 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 (-4.2A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	0.76A	4agdA-6fdyU: 20.0	4agdA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ANQ_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	6fdy	- (-)	7 / 9	LEU U 20 VAL U 28 ALA U 42 GLY U 97 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.70A	4anqA-6fdyU: 22.3	4anqA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ANS_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	6fdy	- (-)	7 / 9	LEU U 20 VAL U 28 ALA U 42 GLY U 97 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.72A	4ansA-6fdyU: 22.3	4ansA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ASD_A_BAXA1500_2 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	6fdy	- (-)	4 / 6	ILE U 69 VAL U 75 CYH U 94 LEU U 144	None DB8 U 301 (-4.8A) DB8 U 301 (-4.2A) DB8 U 301 (-4.8A)	0.75A	4asdA-6fdyU: 20.8	4asdA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4G0V_A_MIXA1301_1 (DNA TOPOISOMERASE 2-BETA)	6fdy	- (-)	4 / 7	ARG U 258 GLY U 200 ILE U 202 GLN U 248	None	1.10A	4g0vA-6fdyU: undetectable	4g0vA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4I22_A_IREA9001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	6fdy	- (-)	9 / 12	LEU U 20 GLY U 21 VAL U 28 ALA U 42 LYS U 44 LEU U 89 MET U 91 GLY U 97 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 ( 4.9A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) None DB8 U 301 (-4.8A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	0.86A	4i22A-6fdyU: 20.2	4i22A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4I41_A_MIXA500_1 (SERINE/THREONINE-PRO TEIN KINASE PIM-1)	6fdy	- (-)	7 / 12	ALA U 42 ASP U 98 ASP U 137 LYS U 139 ASN U 142 LEU U 144 ASP U 157	DB8 U 301 (-3.6A) None None None DB8 U 301 (-4.5A) DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	0.59A	4i41A-6fdyU: 27.6	4i41A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4I41_A_MIXA500_1 (SERINE/THREONINE-PRO TEIN KINASE PIM-1)	6fdy	- (-)	7 / 12	VAL U 28 ALA U 42 ASP U 98 ASP U 137 LYS U 139 ASN U 142 LEU U 144	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) None None None DB8 U 301 (-4.5A) DB8 U 301 (-4.8A)	0.74A	4i41A-6fdyU: 27.6	4i41A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4KS8_A_B49A701_1 (SERINE/THREONINE-PRO TEIN KINASE PAK 6)	6fdy	- (-)	6 / 10	ALA U 42 VAL U 75 MET U 91 PHE U 93 GLY U 97 LEU U 144	DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	0.69A	4ks8A-6fdyU: 28.3	4ks8A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXY_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	6fdy	- (-)	9 / 12	LEU U 20 VAL U 28 ALA U 42 LYS U 44 VAL U 75 MET U 91 GLY U 97 LEU U 144 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	0.79A	4mxyA-6fdyU: 23.5	4mxyA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXY_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	6fdy	- (-)	10 / 12	LEU U 20 VAL U 28 ALA U 42 LYS U 44 VAL U 75 MET U 91 GLY U 97 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.71A	4mxyB-6fdyU: 23.7	4mxyB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXZ_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	6fdy	- (-)	9 / 12	LEU U 20 VAL U 28 ALA U 42 LYS U 44 VAL U 75 MET U 91 GLY U 97 LEU U 144 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	0.79A	4mxzA-6fdyU: 23.5	4mxzA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXZ_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	6fdy	- (-)	10 / 12	LEU U 20 VAL U 28 ALA U 42 LYS U 44 VAL U 75 MET U 91 GLY U 97 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.71A	4mxzB-6fdyU: 23.7	4mxzB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OGR_I_ADNI401_1 (CYCLIN-DEPENDENT KINASE 9)	6fdy	- (-)	6 / 9	ALA U 42 CYH U 94 ASP U 98 ASN U 142 LEU U 144 ASP U 157	DB8 U 301 (-3.6A) DB8 U 301 (-4.2A) None DB8 U 301 (-4.5A) DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	0.68A	4ogrI-6fdyU: 25.7	4ogrI-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OTW_A_DB8A1101_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3)	6fdy	- (-)	7 / 12	LEU U 20 LYS U 44 VAL U 75 GLY U 97 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.80A	4otwA-6fdyU: 20.6	4otwA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OTW_A_DB8A1101_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3)	6fdy	- (-)	7 / 12	LEU U 20 VAL U 28 LYS U 44 VAL U 75 GLY U 97 LEU U 144 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.73A	4otwA-6fdyU: 20.6	4otwA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OU1_A_BEZA302_0 (RETRO-ALDOLASE, DESIGN RA114)	6fdy	- (-)	4 / 8	ILE U 90 LYS U 78 ILE U 43 ALA U 31	None	0.96A	4ou1A-6fdyU: undetectable	4ou1A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QMN_A_DB8A401_1 (SERINE/THREONINE-PRO TEIN KINASE 24)	6fdy	- (-)	6 / 12	ALA U 42 GLU U 62 MET U 91 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 (-3.6A) None DB8 U 301 (-4.8A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.81A	4qmnA-6fdyU: 29.1	4qmnA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4TWP_A_AXIA601_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	9 / 12	LEU U 20 VAL U 28 ALA U 42 LYS U 44 PHE U 93 GLY U 97 ASN U 142 LEU U 144 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.5A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.98A	4twpA-6fdyU: 24.6	4twpA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4TWP_A_AXIA601_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	9 / 12	VAL U 28 ALA U 42 LYS U 44 PHE U 93 GLY U 97 ASN U 142 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.5A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.92A	4twpA-6fdyU: 24.6	4twpA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4TWP_B_AXIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	9 / 12	LEU U 20 VAL U 28 ALA U 42 LYS U 44 PHE U 93 GLY U 97 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	1.05A	4twpB-6fdyU: 24.9	4twpB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4TWP_B_AXIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	9 / 12	LEU U 20 VAL U 28 ALA U 42 PHE U 93 GLY U 97 ASN U 142 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.5A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.88A	4twpB-6fdyU: 24.9	4twpB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4TYJ_A_0LIA801_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	6fdy	- (-)	4 / 6	LEU U 20 VAL U 28 LYS U 44 ILE U 143	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 ( 4.0A) None	0.62A	4tyjA-6fdyU: 21.7	4tyjA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	6 / 11	LEU U 20 ALA U 42 GLY U 97 ASN U 142 LEU U 144 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.5A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.86A	4wa9A-6fdyU: 21.3	4wa9A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	7 / 12	VAL U 28 ALA U 42 LYS U 44 PHE U 93 GLY U 97 LEU U 144 ALA U 156	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.98A	4wa9B-6fdyU: 23.8	4wa9B-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	7 / 12	VAL U 28 ALA U 42 PHE U 93 GLY U 97 ASN U 142 LEU U 144 ALA U 156	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.5A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.82A	4wa9B-6fdyU: 23.8	4wa9B-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WAN_C_ACTC303_0 (BRANCHPOINT-BRIDGING PROTEIN)	6fdy	- (-)	3 / 3	ASP U 191 ARG U 258 PRO U 255	None	1.06A	4wanC-6fdyU: undetectable	4wanC-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XEY_B_1N1B601_1 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	8 / 12	LEU U 20 VAL U 28 ALA U 42 VAL U 75 PHE U 93 GLY U 97 LEU U 144 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.74A	4xeyB-6fdyU: 24.0	4xeyB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AAA_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	6fdy	- (-)	6 / 9	LEU U 20 VAL U 28 ALA U 42 GLY U 97 LEU U 144 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	0.68A	5aaaA-6fdyU: 22.2	5aaaA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AAB_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	6fdy	- (-)	7 / 10	LEU U 20 VAL U 28 ALA U 42 LYS U 44 GLY U 97 LEU U 144 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	0.78A	5aabA-6fdyU: 22.3	5aabA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_A_DB8A800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	6fdy	- (-)	8 / 12	LEU U 20 ALA U 42 PHE U 93 CYH U 94 GLY U 97 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 (-4.2A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.57A	5ajqA-6fdyU: 21.1	5ajqA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_A_DB8A800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	6fdy	- (-)	8 / 12	LEU U 20 GLY U 21 ALA U 42 PHE U 93 CYH U 94 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.9A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 (-4.2A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.84A	5ajqA-6fdyU: 21.1	5ajqA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_A_DB8A800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	6fdy	- (-)	6 / 12	LYS U 44 CYH U 94 GLY U 97 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 ( 4.0A) DB8 U 301 (-4.2A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.76A	5ajqA-6fdyU: 21.1	5ajqA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CU6_A_ACTA403_0 (CASEIN KINASE II SUBUNIT ALPHA)	6fdy	- (-)	4 / 6	TYR U 190 VAL U 194 PRO U 255 ALA U 181	None	0.84A	5cu6A-6fdyU: 24.0	5cu6A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_A_032A401_2 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	6fdy	- (-)	4 / 6	LYS U 44 PHE U 80 VAL U 75 ASP U 157	DB8 U 301 ( 4.0A) None DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	1.11A	5hesA-6fdyU: 6.5	5hesA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HPU_A_IPHA101_0 (INSULIN, CHAIN A INSULIN, CHAIN B)	6fdy	- (-)	4 / 4	CYH U 243 LEU U 207 LEU U 203 ALA U 206	None	1.00A	5hpuA-6fdyU: undetectable 5hpuB-6fdyU: undetectable	5hpuA-6fdyU: undetectable 5hpuB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5K7U_A_SAMA601_0 (N6-ADENOSINE-METHYLT RANSFERASE 70 KDA SUBUNIT)	6fdy	- (-)	5 / 12	PRO U 237 LEU U 239 PHE U 208 ARG U 107 GLY U 209	None	1.08A	5k7uA-6fdyU: undetectable	5k7uA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	6fdy	- (-)	6 / 12	VAL U 28 ALA U 42 VAL U 75 ASP U 98 LEU U 144 ALA U 156	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) None DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.86A	5l2tA-6fdyU: 7.3	5l2tA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MAF_A_XINA403_2 (MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE)	6fdy	- (-)	4 / 5	LEU U 66 CYH U 94 LEU U 144 ASP U 157	None DB8 U 301 (-4.2A) DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	0.80A	5mafA-6fdyU: 28.6	5mafA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	5 / 12	ALA U 42 VAL U 75 HIS U 135 LEU U 144 ALA U 156	DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) None DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.60A	5mo4A-6fdyU: 15.5	5mo4A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OWR_A_1N1A401_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	6fdy	- (-)	4 / 8	ALA U 42 CYH U 94 LEU U 144 ASP U 157	DB8 U 301 (-3.6A) DB8 U 301 (-4.2A) DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	0.30A	5owrA-6fdyU: 23.7	5owrA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OWR_A_1N1A401_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	6fdy	- (-)	4 / 8	GLU U 62 CYH U 94 LEU U 144 ASP U 157	None DB8 U 301 (-4.2A) DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	0.33A	5owrA-6fdyU: 23.7	5owrA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5TE0_A_XINA401_1 (AP2-ASSOCIATED PROTEIN KINASE 1)	6fdy	- (-)	6 / 12	GLU U 18 ALA U 42 VAL U 75 PHE U 93 GLY U 97 LEU U 144	None DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	0.71A	5te0A-6fdyU: 25.3	5te0A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VC3_A_DB8A601_1 (WEE1-LIKE PROTEIN KINASE)	6fdy	- (-)	6 / 12	GLU U 18 GLY U 21 ALA U 42 CYH U 94 GLY U 97 ASP U 157	None DB8 U 301 ( 4.9A) DB8 U 301 (-3.6A) DB8 U 301 (-4.2A) DB8 U 301 ( 4.1A) DB8 U 301 (-3.6A)	0.74A	5vc3A-6fdyU: 26.0	5vc3A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCV_A_1N1A404_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	6fdy	- (-)	6 / 12	LEU U 20 ALA U 42 LYS U 44 VAL U 75 LEU U 89 GLY U 97	DB8 U 301 (-3.7A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) None DB8 U 301 ( 4.1A)	1.37A	5vcvA-6fdyU: 24.8	5vcvA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCY_A_DB8A401_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	6fdy	- (-)	7 / 12	LEU U 20 VAL U 28 ALA U 42 LYS U 44 LEU U 89 CYH U 94 GLY U 96	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) None DB8 U 301 (-4.2A) None	0.80A	5vcyA-6fdyU: 24.4	5vcyA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCY_A_DB8A401_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	6fdy	- (-)	6 / 12	LEU U 20 VAL U 28 ALA U 42 LYS U 44 LEU U 89 GLY U 97	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) None DB8 U 301 ( 4.1A)	0.99A	5vcyA-6fdyU: 24.4	5vcyA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5W5V_A_ANWA701_0 (SERINE/THREONINE-PRO TEIN KINASE TBK1)	6fdy	- (-)	5 / 9	ALA U 42 VAL U 75 MET U 91 CYH U 94 GLY U 96	DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) DB8 U 301 (-4.8A) DB8 U 301 (-4.2A) None	1.05A	5w5vA-6fdyU: 4.1	5w5vA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5W5V_A_ANWA701_0 (SERINE/THREONINE-PRO TEIN KINASE TBK1)	6fdy	- (-)	6 / 9	LEU U 20 ALA U 42 VAL U 75 MET U 91 CYH U 94 GLY U 97	DB8 U 301 (-3.7A) DB8 U 301 (-3.6A) DB8 U 301 (-4.8A) DB8 U 301 (-4.8A) DB8 U 301 (-4.2A) DB8 U 301 ( 4.1A)	0.74A	5w5vA-6fdyU: 4.1	5w5vA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5W97_C_CHDC302_0 (CYTOCHROME C OXIDASE SUBUNIT 1 CYTOCHROME C OXIDASE SUBUNIT 3)	6fdy	- (-)	4 / 7	LEU U 155 ASP U 195 TRP U 269 HIS U 267	None	1.21A	5w97C-6fdyU: undetectable 5w97a-6fdyU: undetectable 5w97c-6fdyU: undetectable	5w97C-6fdyU: undetectable 5w97a-6fdyU: undetectable 5w97c-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5XV7_A_EMHA705_1 (SERINE-ARGININE (SR) PROTEIN KINASE 1)	6fdy	- (-)	5 / 12	LEU U 20 GLY U 21 VAL U 28 ALA U 42 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 ( 4.9A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.2A)	0.49A	5xv7A-6fdyU: 24.0	5xv7A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	6fdy	- (-)	7 / 12	LEU U 20 VAL U 28 ALA U 42 LYS U 44 CYH U 94 GLY U 97 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.2A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	0.89A	5y7zA-6fdyU: 24.3	5y7zA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_B_IREB401_0 (CYCLIN-G-ASSOCIATED KINASE)	6fdy	- (-)	7 / 12	ALA U 42 LYS U 44 LEU U 89 CYH U 94 GLY U 97 LEU U 144 ASP U 157	DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) None DB8 U 301 (-4.2A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	0.94A	5y7zB-6fdyU: 17.6	5y7zB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_B_IREB401_0 (CYCLIN-G-ASSOCIATED KINASE)	6fdy	- (-)	7 / 12	LEU U 20 ALA U 42 LYS U 44 LEU U 89 CYH U 94 GLY U 97 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) None DB8 U 301 (-4.2A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	0.93A	5y7zB-6fdyU: 17.6	5y7zB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_A_1E8A1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	6fdy	- (-)	6 / 12	LEU U 20 GLY U 21 VAL U 28 ALA U 42 LEU U 89 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 ( 4.9A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) None DB8 U 301 (-4.8A)	0.58A	5yu9A-6fdyU: 20.0	5yu9A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_A_LEVA801_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	6fdy	- (-)	3 / 3	LYS U 44 LEU U 144 ASP U 157	DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 (-3.6A)	0.89A	5zv2A-6fdyU: 21.5	5zv2A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD6_A_STIA603_0 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	7 / 12	VAL U 28 ALA U 42 LYS U 44 VAL U 75 PHE U 93 LEU U 144 ALA U 156	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.87A	6hd6A-6fdyU: 21.5	6hd6A-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD6_B_STIB601_0 (TYROSINE-PROTEIN KINASE ABL1)	6fdy	- (-)	7 / 12	LEU U 20 VAL U 28 ALA U 42 LYS U 44 VAL U 75 PHE U 93 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.4A) DB8 U 301 (-4.8A)	0.95A	6hd6B-6fdyU: 21.3	6hd6B-6fdyU: undetectable

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1IEP_A_STIA201_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;PHE U  93;GLY U  97;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.83A","1iepA-6fdyU:22.0","1iepA-6fdyU:undetectable"],["1IEP_A_STIA201_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;PHE U  93;GLY U  97;LEU U 144;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.73A","1iepA-6fdyU:22.0","1iepA-6fdyU:undetectable"],["1IEP_B_STIB202_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;PHE U  93;GLY U  97;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.88A","1iepB-6fdyU:21.8","1iepB-6fdyU:undetectable"],["1OPJ_A_STIA3_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"LEU U  20;VAL U  28;ALA U  42;VAL U  75;PHE U  93;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.2A)","0.75A","1opjA-6fdyU:21.7","1opjA-6fdyU:undetectable"],["1OPJ_B_STIB4_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",7,"VAL U  28;ALA U  42;VAL U  75;PHE U  93;GLY U  97;ALA U 156;ASP U 157","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.99A","1opjB-6fdyU:21.6","1opjB-6fdyU:undetectable"],["2EUF_B_LQQB401_1","CELL DIVISION PROTEIN KINASE 6","6fdy","-","-",6,"VAL U  75;ASP U  98;ASN U 142;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 (-4.8A);None;DB8 U 301 (-4.5A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.54A","2eufB-6fdyU:26.7","2eufB-6fdyU:undetectable"],["2GQG_A_1N1A501_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",8,"LEU U  20;ALA U  42;LYS U  44;VAL U  75;PHE U  93;GLY U  97;LEU U 144;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.67A","2gqgA-6fdyU:25.0","2gqgA-6fdyU:undetectable"],["2GQG_B_1N1B502_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",7,"VAL U  28;ALA U  42;LYS U  44;VAL U  75;GLY U  97;LEU U 144;ALA U 156","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.64A","2gqgB-6fdyU:25.0","2gqgB-6fdyU:undetectable"],["2HYY_A_STIA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"VAL U  28;ALA U  42;PHE U  93;GLY U  97;ALA U 156;ASP U 157","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.83A","2hyyA-6fdyU:22.1","2hyyA-6fdyU:undetectable"],["2HYY_A_STIA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"VAL U  28;ALA U  42;PHE U  93;GLY U  97;LEU U 144;ALA U 156","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.73A","2hyyA-6fdyU:22.1","2hyyA-6fdyU:undetectable"],["2HYY_B_STIB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"VAL U  28;ALA U  42;PHE U  93;GLY U  97;LEU U 144;ALA U 156","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.71A","2hyyB-6fdyU:22.2","2hyyB-6fdyU:undetectable"],["2ITY_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","6fdy","-","-",8,"LEU U  20;GLY U  21;VAL U  28;ALA U  42;LYS U  44;LEU U  89;GLY U  97;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 ( 4.9A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);None;DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","0.68A","2ityA-6fdyU:22.6","2ityA-6fdyU:undetectable"],["2ITY_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","6fdy","-","-",8,"LEU U  20;GLY U  21;VAL U  28;ALA U  42;LYS U  44;LEU U  89;LEU U 144;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.9A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);None;DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","0.83A","2ityA-6fdyU:22.6","2ityA-6fdyU:undetectable"],["2XP2_A_VGHA9000_1","TYROSINE-PROTEIN KINASE RECEPTOR","6fdy","-","-",6,"LEU U  20;VAL U  28;ALA U  42;GLY U  97;LEU U 144;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","0.64A","2xp2A-6fdyU:5.4","2xp2A-6fdyU:undetectable"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",5,"LEU U  20;VAL U  28;LYS U  44;VAL U  75;PHE U  93","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A)","0.69A","3cs9A-6fdyU:21.8","3cs9A-6fdyU:undetectable"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",5,"LEU U  20;VAL U  28;VAL U  75;PHE U  93;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 (-3.6A)","0.92A","3cs9A-6fdyU:21.8","3cs9A-6fdyU:undetectable"],["3G0F_A_B49A9001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;CYH U  94;GLY U  97;ASP U  98;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 (-4.2A);DB8 U 301 ( 4.1A);None;DB8 U 301 (-4.8A)","0.75A","3g0fA-6fdyU:21.6","3g0fA-6fdyU:undetectable"],["3G0F_B_B49B9001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","6fdy","-","-",6,"LEU U  20;VAL U  28;ALA U  42;CYH U  94;GLY U  97;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 (-4.2A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","0.73A","3g0fB-6fdyU:21.9","3g0fB-6fdyU:undetectable"],["3GVU_A_STIA1001_1","TYROSINE-PROTEIN KINASE ABL2","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;VAL U  75;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.87A","3gvuA-6fdyU:22.2","3gvuA-6fdyU:undetectable"],["3IK3_A_0LIA1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",5,"ALA U  42;VAL U  75;HIS U 135;LEU U 144;ALA U 156","DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);None;DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.64A","3ik3A-6fdyU:21.8","3ik3A-6fdyU:undetectable"],["3IK3_B_0LIB2_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",5,"ALA U  42;VAL U  75;HIS U 135;LEU U 144;ALA U 156","DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);None;DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.67A","3ik3B-6fdyU:21.6","3ik3B-6fdyU:undetectable"],["3K5V_A_STIA2_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"VAL U  28;ALA U  42;PHE U  93;GLY U  97;LEU U 144;ALA U 156","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.75A","3k5vA-6fdyU:21.6","3k5vA-6fdyU:undetectable"],["3K5V_B_STIB2_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"VAL U  28;ALA U  42;PHE U  93;GLY U  97;LEU U 144;ALA U 156","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.72A","3k5vB-6fdyU:21.3","3k5vB-6fdyU:undetectable"],["3MS9_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"LEU U  20;VAL U  28;ALA U  42;PHE U  93;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.68A","3ms9A-6fdyU:21.7","3ms9A-6fdyU:undetectable"],["3MS9_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"LEU U  20;VAL U  28;ALA U  42;PHE U  93;LEU U 144;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.70A","3ms9A-6fdyU:21.7","3ms9A-6fdyU:undetectable"],["3MSS_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"LEU U  20;VAL U  28;ALA U  42;PHE U  93;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.69A","3mssA-6fdyU:21.8","3mssA-6fdyU:undetectable"],["3MSS_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"LEU U  20;VAL U  28;ALA U  42;PHE U  93;LEU U 144;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.72A","3mssA-6fdyU:21.8","3mssA-6fdyU:undetectable"],["3MSS_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"LEU U  20;VAL U  28;ALA U  42;PHE U  93;GLY U  97;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 ( 4.2A)","0.71A","3mssB-6fdyU:21.8","3mssB-6fdyU:undetectable"],["3MSS_C_STIC1_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"LEU U  20;VAL U  28;ALA U  42;PHE U  93;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.72A","3mssC-6fdyU:21.8","3mssC-6fdyU:undetectable"],["3MSS_C_STIC1_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"LEU U  20;VAL U  28;ALA U  42;PHE U  93;LEU U 144;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.72A","3mssC-6fdyU:21.8","3mssC-6fdyU:undetectable"],["3MSS_D_STID1_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"LEU U  20;ALA U  42;PHE U  93;GLY U  97;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.86A","3mssD-6fdyU:21.8","3mssD-6fdyU:undetectable"],["3MSS_D_STID1_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"LEU U  20;ALA U  42;PHE U  93;GLY U  97;LEU U 144;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.76A","3mssD-6fdyU:21.8","3mssD-6fdyU:undetectable"],["3PYY_B_STIB4_1","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","6fdy","-","-",6,"LEU U  20;VAL U  28;ALA U  42;VAL U  75;LEU U 144;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.77A","3pyyB-6fdyU:21.7","3pyyB-6fdyU:undetectable"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",7,"LEU U  20;ALA U  42;GLU U  62;VAL U  75;PHE U  93;GLY U  97;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 (-3.6A);None;DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","1.05A","3ue4A-6fdyU:24.4","3ue4A-6fdyU:undetectable"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",7,"LEU U  20;ALA U  42;LYS U  44;VAL U  75;PHE U  93;GLY U  97;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","0.63A","3ue4A-6fdyU:24.4","3ue4A-6fdyU:undetectable"],["3UE4_B_DB8B601_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;VAL U  75;PHE U  93;GLY U  97;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","0.63A","3ue4B-6fdyU:24.4","3ue4B-6fdyU:undetectable"],["3UG2_A_IREA1_1","EPIDERMAL GROWTH FACTOR RECEPTOR","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;LYS U  44;LEU U  89;GLY U  97;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);None;DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","0.49A","3ug2A-6fdyU:23.3","3ug2A-6fdyU:undetectable"],["3UG2_A_IREA1_1","EPIDERMAL GROWTH FACTOR RECEPTOR","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;LYS U  44;LEU U  89;MET U  91;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);None;DB8 U 301 (-4.8A);DB8 U 301 (-4.8A)","0.62A","3ug2A-6fdyU:23.3","3ug2A-6fdyU:undetectable"],["3WZD_A_LEVA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","6fdy","-","-",5,"LEU U  20;VAL U  28;ALA U  42;CYH U  94;GLY U  97","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 (-4.2A);DB8 U 301 ( 4.1A)","0.48A","3wzdA-6fdyU:21.4","3wzdA-6fdyU:undetectable"],["4AG8_A_AXIA2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;LYS U  44;PHE U  93;GLY U  97;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","0.75A","4ag8A-6fdyU:20.9","4ag8A-6fdyU:undetectable"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","6fdy","-","-",7,"LEU U  20;ALA U  42;VAL U  75;PHE U  93;CYH U  94;GLY U  97;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 (-4.2A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","0.76A","4agdA-6fdyU:20.0","4agdA-6fdyU:undetectable"],["4ANQ_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;GLY U  97;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.70A","4anqA-6fdyU:22.3","4anqA-6fdyU:undetectable"],["4ANS_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;GLY U  97;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.72A","4ansA-6fdyU:22.3","4ansA-6fdyU:undetectable"],["4ASD_A_BAXA1500_2","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","6fdy","-","-",4,"ILE U  69;VAL U  75;CYH U  94;LEU U 144","None;DB8 U 301 (-4.8A);DB8 U 301 (-4.2A);DB8 U 301 (-4.8A)","0.75A","4asdA-6fdyU:20.8","4asdA-6fdyU:undetectable"],["4G0V_A_MIXA1301_1","DNA TOPOISOMERASE 2-BETA","6fdy","-","-",4,"ARG U 258;GLY U 200;ILE U 202;GLN U 248","None","1.10A","4g0vA-6fdyU:undetectable","4g0vA-6fdyU:undetectable"],["4I22_A_IREA9001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","6fdy","-","-",9,"LEU U  20;GLY U  21;VAL U  28;ALA U  42;LYS U  44;LEU U  89;MET U  91;GLY U  97;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 ( 4.9A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);None;DB8 U 301 (-4.8A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","0.86A","4i22A-6fdyU:20.2","4i22A-6fdyU:undetectable"],["4I41_A_MIXA500_1","SERINE\/THREONINE-PROTEIN KINASE PIM-1","6fdy","-","-",7,"ALA U  42;ASP U  98;ASP U 137;LYS U 139;ASN U 142;LEU U 144;ASP U 157","DB8 U 301 (-3.6A);None;None;None;DB8 U 301 (-4.5A);DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","0.59A","4i41A-6fdyU:27.6","4i41A-6fdyU:undetectable"],["4I41_A_MIXA500_1","SERINE\/THREONINE-PROTEIN KINASE PIM-1","6fdy","-","-",7,"VAL U  28;ALA U  42;ASP U  98;ASP U 137;LYS U 139;ASN U 142;LEU U 144","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);None;None;None;DB8 U 301 (-4.5A);DB8 U 301 (-4.8A)","0.74A","4i41A-6fdyU:27.6","4i41A-6fdyU:undetectable"],["4KS8_A_B49A701_1","SERINE\/THREONINE-PROTEIN KINASE PAK 6","6fdy","-","-",6,"ALA U  42;VAL U  75;MET U  91;PHE U  93;GLY U  97;LEU U 144","DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","0.69A","4ks8A-6fdyU:28.3","4ks8A-6fdyU:undetectable"],["4MXY_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","6fdy","-","-",9,"LEU U  20;VAL U  28;ALA U  42;LYS U  44;VAL U  75;MET U  91;GLY U  97;LEU U 144;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","0.79A","4mxyA-6fdyU:23.5","4mxyA-6fdyU:undetectable"],["4MXY_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","6fdy","-","-",10,"LEU U  20;VAL U  28;ALA U  42;LYS U  44;VAL U  75;MET U  91;GLY U  97;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.71A","4mxyB-6fdyU:23.7","4mxyB-6fdyU:undetectable"],["4MXZ_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","6fdy","-","-",9,"LEU U  20;VAL U  28;ALA U  42;LYS U  44;VAL U  75;MET U  91;GLY U  97;LEU U 144;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","0.79A","4mxzA-6fdyU:23.5","4mxzA-6fdyU:undetectable"],["4MXZ_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","6fdy","-","-",10,"LEU U  20;VAL U  28;ALA U  42;LYS U  44;VAL U  75;MET U  91;GLY U  97;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.71A","4mxzB-6fdyU:23.7","4mxzB-6fdyU:undetectable"],["4OGR_I_ADNI401_1","CYCLIN-DEPENDENT KINASE 9","6fdy","-","-",6,"ALA U  42;CYH U  94;ASP U  98;ASN U 142;LEU U 144;ASP U 157","DB8 U 301 (-3.6A);DB8 U 301 (-4.2A);None;DB8 U 301 (-4.5A);DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","0.68A","4ogrI-6fdyU:25.7","4ogrI-6fdyU:undetectable"],["4OTW_A_DB8A1101_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","6fdy","-","-",7,"LEU U  20;LYS U  44;VAL U  75;GLY U  97;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.80A","4otwA-6fdyU:20.6","4otwA-6fdyU:undetectable"],["4OTW_A_DB8A1101_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","6fdy","-","-",7,"LEU U  20;VAL U  28;LYS U  44;VAL U  75;GLY U  97;LEU U 144;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.73A","4otwA-6fdyU:20.6","4otwA-6fdyU:undetectable"],["4OU1_A_BEZA302_0","RETRO-ALDOLASE, DESIGN RA114","6fdy","-","-",4,"ILE U  90;LYS U  78;ILE U  43;ALA U  31","None","0.96A","4ou1A-6fdyU:undetectable","4ou1A-6fdyU:undetectable"],["4QMN_A_DB8A401_1","SERINE\/THREONINE-PROTEIN KINASE 24","6fdy","-","-",6,"ALA U  42;GLU U  62;MET U  91;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 (-3.6A);None;DB8 U 301 (-4.8A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.81A","4qmnA-6fdyU:29.1","4qmnA-6fdyU:undetectable"],["4TWP_A_AXIA601_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",9,"LEU U  20;VAL U  28;ALA U  42;LYS U  44;PHE U  93;GLY U  97;ASN U 142;LEU U 144;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.5A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.98A","4twpA-6fdyU:24.6","4twpA-6fdyU:undetectable"],["4TWP_A_AXIA601_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",9,"VAL U  28;ALA U  42;LYS U  44;PHE U  93;GLY U  97;ASN U 142;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.5A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.92A","4twpA-6fdyU:24.6","4twpA-6fdyU:undetectable"],["4TWP_B_AXIB601_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",9,"LEU U  20;VAL U  28;ALA U  42;LYS U  44;PHE U  93;GLY U  97;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","1.05A","4twpB-6fdyU:24.9","4twpB-6fdyU:undetectable"],["4TWP_B_AXIB601_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",9,"LEU U  20;VAL U  28;ALA U  42;PHE U  93;GLY U  97;ASN U 142;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.5A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.88A","4twpB-6fdyU:24.9","4twpB-6fdyU:undetectable"],["4TYJ_A_0LIA801_2","FIBROBLAST GROWTH FACTOR RECEPTOR 4","6fdy","-","-",4,"LEU U  20;VAL U  28;LYS U  44;ILE U 143","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 ( 4.0A);None","0.62A","4tyjA-6fdyU:21.7","4tyjA-6fdyU:undetectable"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",6,"LEU U  20;ALA U  42;GLY U  97;ASN U 142;LEU U 144;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.5A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.86A","4wa9A-6fdyU:21.3","4wa9A-6fdyU:undetectable"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",7,"VAL U  28;ALA U  42;LYS U  44;PHE U  93;GLY U  97;LEU U 144;ALA U 156","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.98A","4wa9B-6fdyU:23.8","4wa9B-6fdyU:undetectable"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",7,"VAL U  28;ALA U  42;PHE U  93;GLY U  97;ASN U 142;LEU U 144;ALA U 156","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.5A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.82A","4wa9B-6fdyU:23.8","4wa9B-6fdyU:undetectable"],["4WAN_C_ACTC303_0","BRANCHPOINT-BRIDGING PROTEIN","6fdy","-","-",3,"ASP U 191;ARG U 258;PRO U 255","None","1.06A","4wanC-6fdyU:undetectable","4wanC-6fdyU:undetectable"],["4XEY_B_1N1B601_1","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",8,"LEU U  20;VAL U  28;ALA U  42;VAL U  75;PHE U  93;GLY U  97;LEU U 144;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.74A","4xeyB-6fdyU:24.0","4xeyB-6fdyU:undetectable"],["5AAA_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","6fdy","-","-",6,"LEU U  20;VAL U  28;ALA U  42;GLY U  97;LEU U 144;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","0.68A","5aaaA-6fdyU:22.2","5aaaA-6fdyU:undetectable"],["5AAB_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;LYS U  44;GLY U  97;LEU U 144;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","0.78A","5aabA-6fdyU:22.3","5aabA-6fdyU:undetectable"],["5AJQ_A_DB8A800_1","SERINE\/THREONINE-PROTEIN KINASE 10","6fdy","-","-",8,"LEU U  20;ALA U  42;PHE U  93;CYH U  94;GLY U  97;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 (-4.2A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.57A","5ajqA-6fdyU:21.1","5ajqA-6fdyU:undetectable"],["5AJQ_A_DB8A800_1","SERINE\/THREONINE-PROTEIN KINASE 10","6fdy","-","-",8,"LEU U  20;GLY U  21;ALA U  42;PHE U  93;CYH U  94;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.9A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 (-4.2A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.84A","5ajqA-6fdyU:21.1","5ajqA-6fdyU:undetectable"],["5AJQ_A_DB8A800_1","SERINE\/THREONINE-PROTEIN KINASE 10","6fdy","-","-",6,"LYS U  44;CYH U  94;GLY U  97;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 ( 4.0A);DB8 U 301 (-4.2A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.76A","5ajqA-6fdyU:21.1","5ajqA-6fdyU:undetectable"],["5CU6_A_ACTA403_0","CASEIN KINASE II SUBUNIT ALPHA","6fdy","-","-",4,"TYR U 190;VAL U 194;PRO U 255;ALA U 181","None","0.84A","5cu6A-6fdyU:24.0","5cu6A-6fdyU:undetectable"],["5HES_A_032A401_2","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","6fdy","-","-",4,"LYS U  44;PHE U  80;VAL U  75;ASP U 157","DB8 U 301 ( 4.0A);None;DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","1.11A","5hesA-6fdyU:6.5","5hesA-6fdyU:undetectable"],["5HPU_A_IPHA101_0","INSULIN, CHAIN A;INSULIN, CHAIN B","6fdy","-","-",4,"CYH U 243;LEU U 207;LEU U 203;ALA U 206","None","1.00A","5hpuA-6fdyU:undetectable;5hpuB-6fdyU:undetectable","5hpuA-6fdyU:undetectable;5hpuB-6fdyU:undetectable"],["5K7U_A_SAMA601_0","N6-ADENOSINE-METHYLTRANSFERASE 70 KDA SUBUNIT","6fdy","-","-",5,"PRO U 237;LEU U 239;PHE U 208;ARG U 107;GLY U 209","None","1.08A","5k7uA-6fdyU:undetectable","5k7uA-6fdyU:undetectable"],["5L2T_A_6ZZA900_1","CYCLIN-DEPENDENT KINASE 6","6fdy","-","-",6,"VAL U  28;ALA U  42;VAL U  75;ASP U  98;LEU U 144;ALA U 156","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);None;DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.86A","5l2tA-6fdyU:7.3","5l2tA-6fdyU:undetectable"],["5MAF_A_XINA403_2","MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE","6fdy","-","-",4,"LEU U  66;CYH U  94;LEU U 144;ASP U 157","None;DB8 U 301 (-4.2A);DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","0.80A","5mafA-6fdyU:28.6","5mafA-6fdyU:undetectable"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",5,"ALA U  42;VAL U  75;HIS U 135;LEU U 144;ALA U 156","DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);None;DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.60A","5mo4A-6fdyU:15.5","5mo4A-6fdyU:undetectable"],["5OWR_A_1N1A401_1","SERINE\/THREONINE-PROTEIN KINASE 10","6fdy","-","-",4,"ALA U  42;CYH U  94;LEU U 144;ASP U 157","DB8 U 301 (-3.6A);DB8 U 301 (-4.2A);DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","0.30A","5owrA-6fdyU:23.7","5owrA-6fdyU:undetectable"],["5OWR_A_1N1A401_1","SERINE\/THREONINE-PROTEIN KINASE 10","6fdy","-","-",4,"GLU U  62;CYH U  94;LEU U 144;ASP U 157","None;DB8 U 301 (-4.2A);DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","0.33A","5owrA-6fdyU:23.7","5owrA-6fdyU:undetectable"],["5TE0_A_XINA401_1","AP2-ASSOCIATED PROTEIN KINASE 1","6fdy","-","-",6,"GLU U  18;ALA U  42;VAL U  75;PHE U  93;GLY U  97;LEU U 144","None;DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","0.71A","5te0A-6fdyU:25.3","5te0A-6fdyU:undetectable"],["5VC3_A_DB8A601_1","WEE1-LIKE PROTEIN KINASE","6fdy","-","-",6,"GLU U  18;GLY U  21;ALA U  42;CYH U  94;GLY U  97;ASP U 157","None;DB8 U 301 ( 4.9A);DB8 U 301 (-3.6A);DB8 U 301 (-4.2A);DB8 U 301 ( 4.1A);DB8 U 301 (-3.6A)","0.74A","5vc3A-6fdyU:26.0","5vc3A-6fdyU:undetectable"],["5VCV_A_1N1A404_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","6fdy","-","-",6,"LEU U  20;ALA U  42;LYS U  44;VAL U  75;LEU U  89;GLY U  97","DB8 U 301 (-3.7A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);None;DB8 U 301 ( 4.1A)","1.37A","5vcvA-6fdyU:24.8","5vcvA-6fdyU:undetectable"],["5VCY_A_DB8A401_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;LYS U  44;LEU U  89;CYH U  94;GLY U  96","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);None;DB8 U 301 (-4.2A);None","0.80A","5vcyA-6fdyU:24.4","5vcyA-6fdyU:undetectable"],["5VCY_A_DB8A401_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","6fdy","-","-",6,"LEU U  20;VAL U  28;ALA U  42;LYS U  44;LEU U  89;GLY U  97","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);None;DB8 U 301 ( 4.1A)","0.99A","5vcyA-6fdyU:24.4","5vcyA-6fdyU:undetectable"],["5W5V_A_ANWA701_0","SERINE\/THREONINE-PROTEIN KINASE TBK1","6fdy","-","-",5,"ALA U  42;VAL U  75;MET U  91;CYH U  94;GLY U  96","DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);DB8 U 301 (-4.8A);DB8 U 301 (-4.2A);None","1.05A","5w5vA-6fdyU:4.1","5w5vA-6fdyU:undetectable"],["5W5V_A_ANWA701_0","SERINE\/THREONINE-PROTEIN KINASE TBK1","6fdy","-","-",6,"LEU U  20;ALA U  42;VAL U  75;MET U  91;CYH U  94;GLY U  97","DB8 U 301 (-3.7A);DB8 U 301 (-3.6A);DB8 U 301 (-4.8A);DB8 U 301 (-4.8A);DB8 U 301 (-4.2A);DB8 U 301 ( 4.1A)","0.74A","5w5vA-6fdyU:4.1","5w5vA-6fdyU:undetectable"],["5W97_C_CHDC302_0","CYTOCHROME C OXIDASE SUBUNIT 1;CYTOCHROME C OXIDASE SUBUNIT 3","6fdy","-","-",4,"LEU U 155;ASP U 195;TRP U 269;HIS U 267","None","1.21A","5w97C-6fdyU:undetectable;5w97a-6fdyU:undetectable;5w97c-6fdyU:undetectable","5w97C-6fdyU:undetectable;5w97a-6fdyU:undetectable;5w97c-6fdyU:undetectable"],["5XV7_A_EMHA705_1","SERINE-ARGININE (SR) PROTEIN KINASE 1","6fdy","-","-",5,"LEU U  20;GLY U  21;VAL U  28;ALA U  42;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 ( 4.9A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.2A)","0.49A","5xv7A-6fdyU:24.0","5xv7A-6fdyU:undetectable"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;LYS U  44;CYH U  94;GLY U  97;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.2A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","0.89A","5y7zA-6fdyU:24.3","5y7zA-6fdyU:undetectable"],["5Y7Z_B_IREB401_0","CYCLIN-G-ASSOCIATED KINASE","6fdy","-","-",7,"ALA U  42;LYS U  44;LEU U  89;CYH U  94;GLY U  97;LEU U 144;ASP U 157","DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);None;DB8 U 301 (-4.2A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","0.94A","5y7zB-6fdyU:17.6","5y7zB-6fdyU:undetectable"],["5Y7Z_B_IREB401_0","CYCLIN-G-ASSOCIATED KINASE","6fdy","-","-",7,"LEU U  20;ALA U  42;LYS U  44;LEU U  89;CYH U  94;GLY U  97;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);None;DB8 U 301 (-4.2A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","0.93A","5y7zB-6fdyU:17.6","5y7zB-6fdyU:undetectable"],["5YU9_A_1E8A1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","6fdy","-","-",6,"LEU U  20;GLY U  21;VAL U  28;ALA U  42;LEU U  89;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 ( 4.9A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);None;DB8 U 301 (-4.8A)","0.58A","5yu9A-6fdyU:20.0","5yu9A-6fdyU:undetectable"],["5ZV2_A_LEVA801_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1","6fdy","-","-",3,"LYS U  44;LEU U 144;ASP U 157","DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 (-3.6A)","0.89A","5zv2A-6fdyU:21.5","5zv2A-6fdyU:undetectable"],["6HD6_A_STIA603_0","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",7,"VAL U  28;ALA U  42;LYS U  44;VAL U  75;PHE U  93;LEU U 144;ALA U 156","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.87A","6hd6A-6fdyU:21.5","6hd6A-6fdyU:undetectable"],["6HD6_B_STIB601_0","TYROSINE-PROTEIN KINASE ABL1","6fdy","-","-",7,"LEU U  20;VAL U  28;ALA U  42;LYS U  44;VAL U  75;PHE U  93;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.4A);DB8 U 301 (-4.8A)","0.95A","6hd6B-6fdyU:21.3","6hd6B-6fdyU:undetectable"]]